| Human HERC5 restricts an early stage of HIV-1 assembly by a mechanism correlating with the ISGylation of Gag MW Woods, JN Kelly, CJ Hattlmann, JGK Tong, LS Xu, MD Coleman, ... Retrovirology 8, 1-18, 2011 | 89 | 2011 |
| Evidence for differential viral oncolytic efficacy in an in vitro model of epithelial ovarian cancer metastasis JG Tong, YR Valdes, JW Barrett, JC Bell, D Stojdl, G McFadden, ... Molecular Therapy-Oncolytics 2, 2015 | 47 | 2015 |
| BRCA2 inhibition enhances cisplatin-mediated alterations in tumor cell proliferation, metabolism, and metastasis M Rytelewski, JG Tong, A Buensuceso, HS Leong, SM Vareki, ... Molecular oncology 8 (8), 1429-1440, 2014 | 38 | 2014 |
| Interferon-induced HERC5 is evolving under positive selection and inhibits HIV-1 particle production by a novel mechanism targeting Rev/RRE-dependent RNA nuclear export MW Woods, JG Tong, SK Tom, PA Szabo, PC Cavanagh, JD Dikeakos, ... Retrovirology 11, 1-17, 2014 | 33 | 2014 |
| Myxoma virus-mediated oncolysis of ascites-derived human ovarian cancer cells and spheroids is impacted by differential AKT activity RJM Correa, M Komar, JGK Tong, M Sivapragasam, MM Rahman, ... Gynecologic oncology 125 (2), 441-450, 2012 | 32 | 2012 |
| Spatial and temporal epithelial ovarian cancer cell heterogeneity impacts Maraba virus oncolytic potential JG Tong, YR Valdes, M Sivapragasam, JW Barrett, JC Bell, D Stojdl, ... BMC cancer 17, 1-13, 2017 | 31 | 2017 |
| Oncolytic virotherapy for ovarian cancer S Li, J Tong, MM Rahman, TG Shepherd, G McFadden Oncolytic virotherapy, 1-21, 2012 | 27 | 2012 |
| Reducing off target viral delivery in ovarian cancer gene therapy using a protease-activated AAV2 vector platform JG Tong, AC Evans, ML Ho, CM Guenther, MJ Brun, J Judd, E Wu, J Suh Journal of controlled release 307, 292-301, 2019 | 16 | 2019 |
| N-terminal serine/threonine motif has diverse and important effects on behavior of multiple AAV serotypes MY Chen, W Chen, J Tong, ML Ho, J Suh Virology 563, 107-115, 2021 | 5 | 2021 |
| Rational design of chimeric antigen receptor T cells against glypican 3 decouples toxicity from therapeutic efficacy MLG Torchia, R Gilbreth, A Merlino, E Sult, N Monks, J Chesebrough, ... Cytotherapy 24 (7), 720-732, 2022 | 4 | 2022 |
| Abstract C77: A novel BRCA2 targeting antisense oligonucleotide sensitizes human tumor cells to chemotherapy and radiotherapy-the induction of ‘complementary lethality’by … M Rytelewski, J Tong, A Buensucesco, S Maleki Vareki, PJ Ferguson, ... Molecular Cancer Therapeutics 12 (11_Supplement), C77-C77, 2013 | 1 | 2013 |
| 112 Rational design of chimeric antigen receptor T cells against glypican 3 decouples toxicity from therapeutic efficacy L Giardino, R Gilbreth, C Chen, E Sult, N Monks, R Tammali, ... Journal for ImmunoTherapy of Cancer 8 (Suppl 3), 2020 | | 2020 |
| Investigation of a Serine/Threonine Motif in Multiple Adeno-Associated Virus Serotypes MY Chen, W Chen, J Tong, ML Ho, J Suh MOLECULAR THERAPY 27 (4), 225-225, 2019 | | 2019 |
| Characterization of a Novel Serine/Threonine Motif in the N-Terminal Region of Adeno-Associated Virus J Tong, T Robinson, M Ho, J Chen, E Lee, B Kang, K Reyes-Gamas, ... MOLECULAR THERAPY 26 (5), 305-306, 2018 | | 2018 |
| Engineering Adeno-Associated Virus with a Self-Peptide for Immune-Avoidance TM Robinson, M Chen, S Butler, J Tong, M Lam, M Ykema, J Suh MOLECULAR THERAPY 26 (5), 306-306, 2018 | | 2018 |
| Characterization of a Protease-Activatable Adeno-Associated Virus Vector for Disease-Targeted Gene Delivery A Evans, J Tong, M Ho, C Guenther, M Brun, J Suh MOLECULAR THERAPY 26 (5), 303-304, 2018 | | 2018 |
| Oncolytic Virus Therapy for the Treatment of Metastatic Ovarian Cancer J Tong The University of Western Ontario (Canada), 2016 | | 2016 |
| A BRCA2-targeting antisense oligodeoxynucleotide enhances cisplatin effectiveness by decreasing human tumor cell proliferation, metastatic frequency, and metabolic response M Rytelewski, J Tong, A Buensuceso, H Leong, P Ferguson, SM Vareki, ... Cancer Research 74 (19_Supplement), 1687-1687, 2014 | | 2014 |
| Cellular Restriction Factors: Exploiting the Body’s Antiviral Proteins to Combat HIV-1/AIDS JN Kelly, JGK Tong, CJ Hattlmann, MW Woods, SD Barr HIV and AIDS-Updates on Biology, Immunology, Epidemiology and Treatment …, 2011 | | 2011 |
| Characterization of the HIV-1 Restriction Factor Herc5 JGK Tong | | 2011 |
